Skip to main content

Table 2 Patient characteristics

From: Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma

Characteristic Number (%)
Sex  
Male 39 (92.9%)
Female 3 (7.1%)
Age  
≤55 12 (28.6%)
>55 30 (71.4%)
Race  
White 37 (88.1%)
Not white 5 (11.9%)
KPS  
90-100 34 (81.0%)
60-80 8 (19.0%)
Primary site  
Tonsil 13 (31.0%)
Base of tongue 29 (69.0%)
Pharyngeal wall 0 (0%)
Soft palate 0 (0%)
T stage  
T1 7 (16.7%)
T2 21 (50.0%)
T3 6 (14.3%)
T4 8 (19.0%)
N stage  
N0 0 (0%)
N1 2 (4.8%)
N2 34 (81.0%)
N3 6 (14.3%)
AJCC Stage  
I 0 (0%)
II 0 (0%)
III 1 (2.4%)
IV 41 (97.6%)
Tobacco exposure  
Never smoked 8 (19.0%)
Former smoker 26 (61.9%)
Current smoker 7 (16.7%)
Number of pack years  
Median (range) 8 (0–84)
Neck dissection before radiation  
No 42 (100%)
Yes 0 (0%)
Chemotherapy 42 (100%)
Concurrent 38 (90.5%)
Cisplatin 20 (47.6%)
Carboplatin/5-FU 1 (2.4%)
Carboplatin/paclitaxel 1 (2.4%)
Cetuximab 11 (26.2%)
Cisplatin/bevacizumab 5 (11.9%)
Induction + concurrent 3 (7.1%)
  1. Abbreviations: AJCC American Joint Committee on Cancer, 5-FU 5-fluorouracil, KPS Karnofsky performance status.